Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) submitted a U.S. regulatory application for cemdisiran, an investigational treatment for generalized myasthenia gravis (gMG) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE